Team:Freiburg/Project/truncation

From 2013.igem.org

(Difference between revisions)
Line 55: Line 55:
<p class="first_order"><a href="https://2013.igem.org/Team:Freiburg/Project/modeling"> Modeling </a></p>
<p class="first_order"><a href="https://2013.igem.org/Team:Freiburg/Project/modeling"> Modeling </a></p>
<p class="first_order"><a href="https://2013.igem.org/Team:Freiburg/Project/truncation" class="active"> Truncation </a></p>
<p class="first_order"><a href="https://2013.igem.org/Team:Freiburg/Project/truncation" class="active"> Truncation </a></p>
 +
<p class="first_order"><a href="https://2013.igem.org/Team:Freiburg/Project/application"> Application </a></p>
</div>
</div>

Revision as of 15:21, 24 October 2013


Truncation of the dCas9 protein

Reason for truncating dCas9

With a size of 160 kDa, the dCas9 protein of the CRISPR/Cas system is the largest molecular tool among Zinc Fingers and Transcription Activator–Like Effectors. Difficulties that occurred during the light induced translocation of a dCas9 fusion construct in the nucleus indicated, that the size of dCas9 might be a bottleneck for efficient genome engineering hence a truncation strategy was developed.

Truncation of dCas9

How to truncate dCas9

To reduce the size of dCas9 we ran a PCR over the backbone with two primers binding in dCas9, one with an overlap for Gibson Assembly. After the PCR one-fragment gibson cloning was performed. We tried five different strategies where to reduce the size of the dCas9 protein. In the first attempt we deleted 365 bp near the N-terminus of the protein. In a second try we erased 306 bp near the C-terminal part of dCas9. Here we assume the reverse transcription domain of the protein, which will probably be responsible for DNA binding. Therefore this truncation is thought to verify this assumption and can serve as a negative control. For truncation 3, 4, and 5 we just deleted the beginning, the middle and the end of dCas9 more drastically by throwing out about 1000 bp.

Figure 10: Design of the truncated dCas9 versions.
dCas9 is flanked by NLS sequences and tagged by a HA epitope. The CMV promoter and the BGH terminator were chosen to control gene expression. You can find truncation 1 in the registry under BBa_K1150047, truncation 2 under BBa_K1150048, truncation 3 BBa_K1150049, truncation 4 under BBa_K1150050 and truncation 5 under BBa_K1150051.

Results

The PCR over the pSB1C3 backbone of the dCas9 plasmid worked for all primer pairs. The different lengths of the PCR products, due to differently truncated dCas9, are clearly visible. After Gibson assembly with these PCR products the test digest of the plasmids also showed the expected length. We cut with NotI so that the insert of the plasmid is cut out. Only for truncation 4 we received a shorter fragment than expected. To ensure the expression of the shortened dCas9 version we transfected the midi-preps of them into HEK-293T cells and performed a western blot analysis of the cell lysates. As it can be seen in figure 10 we could proof the expression of the standardized truncations. As expected truncations 1 and 2 are about 100 amino acids shorter resulting in an approximately 11 kDa shift in the western blot compared to the full-lengths dCas9. Truncation 3 and 5 run at around 120 kDa. Here about 300bp are missing, resulting in a size reduction of about 33kDa. Only truncation 4 is shorter than expected. It has about 80 kDa and the sequencing of the midi-prep of T4 revealed a nearly 2000 bp deletion in the dCas9.

Figure 11: Western blot with anti HA-antibody to show the expression of the different truncations.
HEK-293T cells were transfected with 5 different truncated CMV:dCas9 constructs in pSB1C3 and the EMX1 RNAimer plasmid in 6-well plates. 42 hours post transfection cells were taken up in 500 µl optimized dilution buffer. 170 µl were centrifuged, pelleted cells were resuspended in SDS sample buffer and used for semi-dry western blotting. All truncations are expressed (upper bands in T1-5) and could be detected via the HA-tagged dCas9. Only truncation 4 is smaller than expected.

After the proof of expression we tested the binding capacity of the truncated dCas9 versions to DNA with the uniBAss ELISA (see Results of uniBAss). By now we could not show binding of the untruncated dCas9 in pSB1C3 no matter of CMV or SV40 promoter. This is due to a very weak expression of dCas9 in pSB1C3 which results in amounts of dCas9 which are not sufficient for uniBAss detection levels. Because we cannot prove the binding of the full-length dCas9 in the iGEM backbone, we are not able to make a statement about the binding capacity of the truncated versions. At the moment we are trying to increase the amount of dCas9 for uniBAss to be above threshold.